Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys

Virology

Volumn 407, Issue 1, 2010, Pages 1-6

  Ersching, Jonatan ^a   Hernandez, Malva I M ^a   Cezarotto, Fabrizzio S ^b   Ferreira, Jovino D S ^a   Martins, Amely B ^c   Switzer, William M ^e   Xiang, Zhiquan ^d   Ertl, Hildegund C J ^d   Zanetti, Carlos R ^a   Pinto, Aguinaldo R ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Centro de Hematologia e Hemoterapia do Acre   (Brazil)

^c INSTITUTO CHICO MENDES DE CONSERVAÇÃO DA BIODIVERSIDADE   (Brazil)

^d WISTAR INSTITUTE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Human adenovirus; Neutralizing antibody; Seroneutralization assay; Simian adenovirus; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAZIL; CHIMPANZEE; CONTROLLED STUDY; HUMAN; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS 26; HUMAN ADENOVIRUS 5; IMMUNITY; MAJOR CLINICAL STUDY; MARMOSET; MONKEY; NONHUMAN; PRIORITY JOURNAL; SEROPREVALENCE; SEROTYPE; SIMIAN VIRUS; SIMIAN VIRUS 6; SIMIAN VIRUS 68; VIRUS NEUTRALIZATION; ADENOVIRUS INFECTION; ADOLESCENT; ADULT; AGED; ANIMAL; BLOOD; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PLATYRRHINI; PRIMATE DISEASE; VETERINARY; VIROLOGY; YOUNG ADULT;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRAZIL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATYRRHINI; PRIMATE DISEASES; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

ADENOVIRIDAE; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; PAN; PLATYRRHINI; SIMIAE; SIMIAN ADENOVIRUS;

EID: 77956934789     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.07.043     Document Type: Article

References (28)

1. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., Holterman L., Damen I., Vogels R., Thorner A.R., O'Brien K.L., Carville A., Mansfield K.G., Goudsmit J., Havenga M.J., Barouch D.H. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 2007, 81:4654-4663.
2. Appaiahgari M.B., Pandey R.M., Vrati S. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin. Vaccine Immunol. 2007, 14:1053-1055.
3. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 2004, 172:6290-6297.
4. Benkö M., Harrach B. Molecular evolution of adenoviruses. Curr. Top. Microbiol. Immunol. 2003, 272:3-35.
5. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893. Step Study Protocol Team.
6. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K.A., Dubey S., Zhu D.M., Nawrocki D., Mach H., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith J.G., Wang S., Liu X., Guan L., Long R., Trigona W., Heidecker G.J., Perry H.C., Persaud N., Toner T.J., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B., Emini E.A., Shiver J.W. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 2003, 77:6305-6313.
7. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Gu L., Martin J.E., Novik L., Chakrabarti B.K., Butman B.T., Gall J.G., King C.R., Andrews C.A., Sheets R., Gomez P.L., Mascola J.R., Nabel G.J., Graham B.S. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 2006, 194:1638-1649. Vaccine Research Center 006 Study Team.
8. ClinicalTrials, 2010. (accessed June 15, 2010). http://clinicaltrials.gov/.
9. Davis A.R., Wivel N.A., Palladino J.L., Tao L., Wilson J.M. Construction of adenoviral vectors. Mol. Biotechnol. 2001, 18:63-70.
10. de Alencar B.C., Persechini P.M., Haolla F.A., de Oliveira G., Silverio J.C., Lannes-Vieira J., Machado A.V., Gazzinelli R.T., Bruna-Romero O., Rodrigues M.M. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect. Immun. 2009, 77:4383-4395.
11. Dudareva M., Andrews L., Gilbert S.C., Bejon P., Marsh K., Mwacharo J., Kai O., Nicosia A., Hill A.V. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27:3501-3504.
12. Farina S.F., Gao G.P., Xiang Z.Q., Rux J.J., Burnett R.M., Alvira M.R., Marsh J., Ertl H.C., Wilson J.M. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 2001, 75:11603-11613.
13. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., Vogels R., Bakker M., Berkhout B., Havenga M., Goudsmit J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004, 18:1213-1216.
14. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., Mbewe B., Pitisuttithum P., Schechter M., Vardas E., Wolfe N.D., Aste-Amezaga M., Casimiro D.R., Coplan P., Straus W.L., Shiver J.W. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28:950-957.
15. Mu J., Jeyanathan M., Small C.L., Zhang X., Roediger E., Feng X., Chong D., Gauldie J., Xing Z. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis. Mol. Ther. 2009, 17:1093-10100.
16. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., Robbins P.D., Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 2004, 11:351-357.
17. Pilankatta R., Chawla T., Khanna N., Swaminathan S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J. Med. Virol. 2010, 82:407-414.
18. Pinto A.R., Fitzgerald J.C., Gao G.P., Wilson J.M., Ertl H.C. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine 2004, 22:697-703.
19. Reyes-Sandoval A., Fitzgerald J.C., Grant R., Roy S., Xiang Z.Q., Li Y., Gao G.P., Wilson J.M., Ertl H.C. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 2004, 78:7392-7399.
20. Roy S., Vandenberghe L.H., Kryazhimskiy S., Grant R., Calcedo R., Yuan X., Keough M., Sandhu A., Wang Q., Medina-Jaszek C.A., Plotkin J.B., Wilson J.M. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog. 2009, 5:e1000503.
21. Shott J.P., McGrath S.M., Pau M.G., Custers J.H., Ophorst O., Demoitié M.A., Dubois M.C., Komisar J., Cobb M., Kester K.E., Dubois P., Cohen J., Goudsmit J., Heppner D.G., Stewart V.A. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 2008, 26:2818-2823.
22. Souza A.P., Haut L., Silva R., Ferreira S.I., Zanetti C.R., Ertl H.C., Pinto A.R. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus. Vaccine 2007, 25:109-116.
23. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., Goudsmit J., Havenga M.J., Kostense S. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 2003, 41:5046-5052.
24. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., Lifton M.A., Essex M., Walker B.D., Goudsmit J., Havenga M.J., Barouch D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 2005, 174:7179-7185.
25. Tatsis N., Ertl H.C.J. Adenoviruses as vaccine vectors. Mol. Ther. 2004, 10:616-629.
26. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., Lemckert A.A., Dilraj A., McNally L.M., Jeena P.M., Jepsen S., Abbink P., Nanda A., Swanson P.E., Bates A.T., O'Brien K.L., Havenga M.J., Goudsmit J., Barouch D.H. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 2006, 44:3781-3783.
27. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., Wilson J.M., Ertl H.C. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 2002, 76:2667-2675.
28. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., Kalish M.L., Ertl H.C. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 2006, 12:1596-1599.